Chuanchom Sakondhavat
Kean University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Chuanchom Sakondhavat.
International Journal of Std & Aids | 1997
Chuanchom Sakondhavat; Yuthapong Werawatanakul; Anthony Bennett; Chusri Kuchaisit; Sugree Suntharapa
Brothel workers in Thailand are at high risk of HIV infection but they alone do not have adequate bargaining power to insist on condom use with all clients. Brothel managers, on the other hand, are a source of influence over both clients and their workers and can promote universal condom use in their establishments. To test whether brothel managers in Khon Kaen City would adopt and successfully implement a condom-only policy in their establishments, all 24 brothel managers in Khon Kaen City attended a meeting on the dangers of HIV and benefits of an all-condom policy. Ideas on how to implement the policy were discussed. Follow-up visits were made once a month to brothels to resupply condoms, provide reinforcement and to collect data. All brothel managers approved of the condom-only in principle and are now implementing the policy. Results of the evaluation of condom use and degree of solidarity in these 24 brothels are available for the AIDS prevention programme. However, a condom-only policy in brothels can only succeed if managers and brothel workers show solidarity in rejecting all noncondom using clients. Laws to promote condom use may not be needed if brothels are given the opportunity to implement a condom-only policy using their own resourcefulness and determination.
International Journal of Std & Aids | 2002
Chuanchom Sakondhavat
Condoms are a highly effective means of preventing human immunode® ciency virus (HIV) transmission and their use is increasing in many parts of the world. Currently, the only widely-available effective method to prevent the heterosexual transmission of HIV is the use of male condoms. However, even where HIV prevalence is high, as is the case in some developing countries, condom promotion projects, involving constant condom availability and regular counselling, have been unable to attain levels of use above 70% except in limited targeted populations1,2. The world’s ® rst female condom (Reality, Femidom, and Femy are all registered names for the female condom) became available to the public in 1992. For ® ve years prior to its introduction in 1992 and continuing since then, clinical studies have been conducted to evaluate ef® cacy, acceptability and safety. The studies have satis® ed ef® cacy, safety, and acceptability standards established by government regulatory bodies including the United States Food and Drug Administration (FDA), and the product has received the European CE mark. Additional studies addressing operational issues, such as introduction strategies, education,marketing and distribution programmes, are increasing trial, acceptance and availability of the female condom, particularly to at-risk populations. The female condom extends the choice of contraceptive methods available and provides signi® cant protection from the risk of pregnancy and infection with sexually transmitted diseases (STDs). Most women andmen participating in the clinical studies report that the female condom is acceptable and allows them to practise safer sex that is sensitive and pleasurable. Data from studies around the world have highlighted the need for female-controlled prevention methods. Non-consensual sex, fear of violence, economic dependence, and inability to negotiate male condom use restrict prevention options for many women3. Although the female condom requires male cooperation, it does not require male initiative. Most importantly, use of the female condom reduces the number of unprotected acts of sexual intercourse, thereby decreasing the risk of pregnancy and increasing protection against transmission of STDs, including HIV. AIDS is now a leading cause of death among women in developing countries4. Women at all ages are biologically at higher risk than men for contracting HIV5. The majority of these infections are transmitted through vaginal intercourse; the presence of other STD infections can substantially increase women’s chances of becoming infected with HIV6. The design of the female condom offers an extra measure of safety to women that the male condom does not. Because the outer ring of the female condom partially covers the external genitalia7, the female condom may be particularly bene® cial in preventing infections caused by genital ulcer pathogens, such as herpes and chancroid. Furthermore, the female condom covers the vaginal mucosa, and thus may provide better protection from STDs than diaphragms, sponges, and caps that cover the cervical mucosa only8. In vitro studies have shown that the female condom provides an effective barrier to passage of microorganisms including HIV9,10. The female condom blocked passage of a bacteriophage smaller than hepatitis B, the smallest virus known to cause an STD, and one-quarter the size of HIV. One study of STD reinfection rates in 104 sexually active women with documented trichomonas and/or chlamydia infection demonstrated that none of the 54 participants who consistently used the female condom were reinfected. Non-compliant users and the control group had trichomonas reinfection rates of 14.7% and 14%, respectively. Three non-compliant users were reinfected with chlamydia11. In a study of Thai sex workers12 randomly allocated to receive either male or female condoms, there was a 25% reduction in the geometric mean incidence rate of STDs in the sex establishments using the female condom compared with those using the male condom (2.81/1000 vs. 3.69/100 women-weeks). Using an acceptable statistical model and extrapolating from failure rates for correct and consistent use, calculations estimate a 97.1% reduction in the risk of HIV infection for each act of intercourse with correct use of the female condom13. International Journal of STD & AIDS 2002; 13: 444± 448
Journal of the Medical Association of Thailand Chotmaihet thangphaet | 2001
Chuanchom Sakondhavat; Weeravatrakul Y; Benette T; Pinitsoontorn P; Kuchaisit C; Kukieattikool P; Pongsatra K
Journal of the Medical Association of Thailand Chotmaihet thangphaet | 1988
Chuanchom Sakondhavat; Kanato M; Leungtongkum P; Kuchaisit C
Srinagarind Medical Journal (SMJ) - ศรีนครินทร์เวชสาร | 2006
Sukree Soontrapa; Suppasin Soontrapa; La-or Chailurkit; Chuanchom Sakondhavat; Srinaree Kaewrudee; Woraluk Somboonporn; Kesorn Loa-unka
Journal of the Medical Association of Thailand Chotmaihet thangphaet | 2006
Kullathida Sowapat; Sukree Soontrapa; Chuanchom Sakondhavat
Journal of the Medical Association of Thailand Chotmaihet thangphaet | 2006
Wachara Saranyaratana; Chuanchom Sakondhavat; Songkwan Silaruks; Sukree Soontrapa; Srinaree Kaewrudee
Journal of the Medical Association of Thailand Chotmaihet thangphaet | 1998
Chuanchom Sakondhavat; Weerasit Sittitrai; Sugree Soontharapa; Yuthapong Werawatanakul; Pattamavadee Pinitsoontorn
Srinagarind Medical Journal (SMJ) - ศรีนครินทร์เวชสาร | 2007
Molruedee Prasit; Chuanchom Sakondhavat; Kesorn Lao-unka; Sugree Soontrapa; Srinaree Kaewrudee; Woraluk Somboonporn; Piangjit Tharnprisan
Journal of the Medical Association of Thailand Chotmaihet thangphaet | 2000
Chuanchom Sakondhavat; Weerasit Sittitrai; Sugree Soontharapa; Yuthapong Veerawatanatrakul; Dusadee Aryuvatana; Pannee Kukieattikool